Clinical Trial Update: Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Epothilone D as second-line treatment for advanced or metastatic refractory colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Epothilone D (epothilone D)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED